Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $546,592.63 in Stock

by · The Cerbat Gem

Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) CTO Metin Kurtoglu sold 32,789 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $16.67, for a total value of $546,592.63. Following the transaction, the chief technology officer now owns 51,033 shares in the company, valued at $850,720.11. This trade represents a 39.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Metin Kurtoglu also recently made the following trade(s):

  • On Monday, November 18th, Metin Kurtoglu sold 34,400 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $18.39, for a total value of $632,616.00.
  • On Thursday, November 14th, Metin Kurtoglu sold 25,900 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.44, for a total value of $425,796.00.

Cartesian Therapeutics Stock Performance

Shares of RNAC traded down $0.32 on Thursday, hitting $16.62. 94,138 shares of the stock traded hands, compared to its average volume of 95,843. Cartesian Therapeutics, Inc. has a one year low of $11.66 and a one year high of $42.60. The company has a market capitalization of $422.48 million, a PE ratio of -0.32 and a beta of 0.63. The business has a 50 day simple moving average of $19.45 and a 200 day simple moving average of $20.11.

Institutional Trading of Cartesian Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. purchased a new stake in shares of Cartesian Therapeutics during the first quarter valued at $4,105,000. Logos Global Management LP purchased a new stake in shares of Cartesian Therapeutics during the 2nd quarter valued at about $2,431,000. BNP Paribas Financial Markets bought a new stake in shares of Cartesian Therapeutics in the first quarter worth approximately $38,000. American International Group Inc. bought a new position in shares of Cartesian Therapeutics in the 1st quarter worth approximately $37,000. Finally, SG Americas Securities LLC purchased a new position in shares of Cartesian Therapeutics during the 1st quarter worth $31,000. Institutional investors own 86.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on RNAC shares. Needham & Company LLC reissued a “buy” rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research report on Friday, November 8th. TD Cowen initiated coverage on Cartesian Therapeutics in a research report on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, HC Wainwright reduced their price objective on Cartesian Therapeutics from $45.00 to $41.00 and set a “buy” rating for the company in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Cartesian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

View Our Latest Report on RNAC

About Cartesian Therapeutics

(Get Free Report)

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

Further Reading